Scarica l'app Stockscreener
67.53
2.07%
1.37
Dopo l'orario di chiusura:
66.97
-0.56
-0.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$66.16
Aprire:
$66.04
Volume 24 ore:
1.55M
Relative Volume:
0.73
Capitalizzazione di mercato:
$12.30B
Reddito:
$381.03M
Utile/perdita netta:
$-1.01B
Rapporto P/E:
-11.35
EPS:
-5.95
Flusso di cassa netto:
$-789.25M
1 W Prestazione:
-0.87%
1M Prestazione:
-4.62%
6M Prestazione:
-7.68%
1 anno Prestazione:
+186.14%
Intervallo 1D:
$65.56
$67.65
Intervallo di 1 settimana:
$64.84
$68.99
Portata 52W:
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
67.53 | 12.41B | 381.03M | -1.01B | -789.25M | -5.95 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis - marketscreener.com
Insmed (INSM) Highlights Promising Brensocatib Trial Results at - GuruFocus
Insmed (INSM) Highlights Promising Brensocatib Trial Results at ATS 2025 | INSM Stock News - GuruFocus
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study - Yahoo Finance
Captrust Financial Advisors Sells 631 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Position in Insmed Incorporated (NASDAQ:INSM) - Defense World
HC Wainwright Issues Optimistic Outlook for Insmed Earnings - Defense World
INSMED Executives Sell Shares to Satisfy Tax Obligations - TradingView
Jefferies Financial Group Initiates Coverage on Insmed (NASDAQ:INSM) - Defense World
Jefferies Initiates Coverage of Insmed (BIT:1INSM) with Buy Recommendation - Nasdaq
Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Jefferies Initiates Coverage of Insmed (BMV:INSM) with Buy Recommendation - Nasdaq
Jefferies sets $105 target on Insmed stock with Buy rating By Investing.com - Investing.com Nigeria
Insmed at Bank of America 2025 Healthcare Conference: Strategic Pipeline Focus - Investing.com
Jefferies Initiates Coverage on INSM with a Buy Rating and $105 PT | INSM Stock News - GuruFocus
Jefferies Initiates Coverage of Insmed (LSE:0JAV) with Buy Recommendation - Nasdaq
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Coverage of Insmed (INSM) with Buy Recommendation - Nasdaq
Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target - marketscreener.com
Jefferies sets $105 target on Insmed stock with Buy rating - Investing.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - Defense World
Insmed (INSM) Gains Buy Rating from Jefferies with Promising Out - GuruFocus
Insmed (INSM) Receives Reaffirmed Buy Rating from HC Wainwright - GuruFocus
Analyst Expectations For Insmed's Future - Benzinga
Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of “Buy” by Analysts - Defense World
UBS Group Cuts Insmed (NASDAQ:INSM) Price Target to $109.00 - Defense World
Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Q1 2025 Earnings Call Transcript - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | I - GuruFocus
UBS Maintains Buy Rating, Lowers Price Target for Insmed (INSM) - GuruFocus
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - TradingView
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain? - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | INSM Stock News - GuruFocus
RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating - marketscreener.com
Insmed: Q1 Earnings Snapshot - Greenwich Time
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed’s Earnings Call: Strong Growth and Optimistic Outlook - TipRanks
Insmed Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Insmed Q1 2025 shows mixed results with slight EPS miss - Investing.com
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained - marketscreener.com
Insmed (INSM) Reports Q1 Revenue Surpassing Expectations and Awaits Key Approvals | INSM Stock News - GuruFocus
Insmed Q1 2025 slides: ARIKAYCE sales surge 23% as brensocatib launch approaches - Investing.com
Insmed earnings missed by $0.07, revenue topped estimates - Investing.com
Insmed Inc (INSM) Q1 2025 Earnings: Revenue Hits $92.8 Million, Surpassing Estimates - GuruFocus
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):